Drug
Ksi 301
Ksi 301: highest development phase Phase 3, developed by Kodiak Sciences. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Kodiak Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| KSI-301 NCT04592419 | Phase 3 | Macular Edema |
| KSI-301 NCT04964089 | Phase 3 | Wet Age-related Macular Degeneration |
| KSI-301 NCT04611152 | Phase 3 | Diabetic Macular Edema |
| KSI-301 NCT04603937 | Phase 3 | Diabetic Macular Edema |
| KSI-301 NCT05066230 | Phase 3 | Non-proliferative Diabetic Retinopathy |
| KSI-301 NCT04049266 | Phase 2/3 | Wet Macular Degeneration |
| KSI-301 NCT03790852 | Phase 1 | Wet Age-related Macular Degeneration |
Latest
No recent events.
Follow Ksi 301 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.